Robeco Institutional Asset Management B.V. Sells 169,034 Shares of BioMarin Pharmaceutical Inc. $BMRN

Key Points

• Robeco Institutional Asset Management cut its BioMarin stake by 18.1%, selling 169,034 shares and leaving 766,432 shares valued at about $45.55 million (roughly 0.40% of the company) at the end of the quarter.
• Company insiders also sold stock: EVP Charles Greg Guyer sold 16,486 shares for about $996,744 and EVP Gregory R. Friberg sold 6,326 shares for about $381,964, with insiders now owning 0.85% of the shares.
• Analysts remain mostly positive, with a consensus "Moderate Buy" rating and an average price target of $90; institutional ownership is very high at 98.71% and the company has a market cap of roughly $10.55 billion.

Robeco Institutional Asset Management B.V. reduced its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 18.1% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 766,432 shares of the biotechnology company's stock after selling 169,034 shares during the quarter. Robeco Institutional Asset Management B.V. owned about 0.40% of BioMarin Pharmaceutical worth $45,549,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the business. V Square Quantitative Management LLC bought a new stake in shares of BioMarin Pharmaceutical in the 4th quarter worth approximately $45,000. 4WEALTH Advisors Inc. bought a new stake in shares of BioMarin Pharmaceutical in the 4th quarter worth approximately $212,000. Perpetual Ltd grew its position in shares of BioMarin Pharmaceutical by 425.7% in the 4th quarter. Perpetual Ltd now owns 25,621 shares of the biotechnology company's stock worth $1,523,000 after buying an additional 20,747 shares during the last quarter. Tema Etfs LLC bought a new stake in shares of BioMarin Pharmaceutical in the 4th quarter worth approximately $319,000. Finally, Nisa Investment Advisors LLC grew its position in shares of BioMarin Pharmaceutical by 7.7% in the 4th quarter. Nisa Investment Advisors LLC now owns 2,741 shares of the biotechnology company's stock worth $163,000 after buying an additional 195 shares during the last quarter. 98.71% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. Wolfe Research reiterated an "outperform" rating on shares of BioMarin Pharmaceutical in a research report on Monday, March 16th. Stifel Nicolaus set a $68.00 price target on BioMarin Pharmaceutical in a research report on Tuesday, February 24th. Sanford C. Bernstein lifted their price target on BioMarin Pharmaceutical from $90.00 to $94.00 and gave the company an "outperform" rating in a research report on Wednesday, February 25th. Oppenheimer dropped their price target on BioMarin Pharmaceutical from $98.00 to $95.00 and set an "outperform" rating on the stock in a research report on Tuesday, February 24th. Finally, Canaccord Genuity Group lifted their price target on BioMarin Pharmaceutical from $98.00 to $104.00 and gave the company a "buy" rating in a research report on Thursday, February 26th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and seven have given a Hold rating to the stock. Based on data from MarketBeat.com, BioMarin Pharmaceutical presently has an average rating of "Moderate Buy" and a consensus price target of $90.00.

Insiders Place Their Bets

In other BioMarin Pharmaceutical news, EVP Charles Greg Guyer sold 16,486 shares of BioMarin Pharmaceutical stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $60.46, for a total transaction of $996,743.56. Following the completion of the transaction, the executive vice president owned 79,953 shares in the company, valued at approximately $4,833,958.38. The trade was a 17.09% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Gregory R. Friberg sold 6,326 shares of BioMarin Pharmaceutical stock in a transaction on Thursday, February 26th. The shares were sold at an average price of $60.38, for a total value of $381,963.88. Following the transaction, the executive vice president owned 37,578 shares of the company's stock, valued at $2,268,959.64. The trade was a 14.41% decrease in their position. The SEC filing for this sale provides additional information. 0.85% of the stock is currently owned by insiders.

BioMarin Pharmaceutical Trading Up 0.6%

NASDAQ BMRN opened at $54.88 on Tuesday. The company has a quick ratio of 3.50, a current ratio of 5.21 and a debt-to-equity ratio of 0.10. BioMarin Pharmaceutical Inc. has a twelve month low of $50.76 and a twelve month high of $66.28. The firm has a market capitalization of $10.55 billion, a PE ratio of 30.83, a P/E/G ratio of 0.54 and a beta of 0.29. The stock's 50 day moving average is $58.28 and its 200 day moving average is $56.31.

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company's commercial portfolio includes several approved therapies targeting inherited disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.